Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria

NCT07545681 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07545681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 28, 2026
Completion date
July 29, 2027
Enrollment
70 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, falciparum